Literature DB >> 16890077

Management of recurrent sinus disease in children with cystic fibrosis: a combined approach.

Anat Shatz1.   

Abstract

OBJECTIVE: To determine whether a combined approach (CA) consisting of functional endoscopic sinus surgery (FESS), Caldwell-Luc operation, and medial maxillectomy is beneficial for children with cystic fibrosis (CF) with refractory sinonasal disease previously treated with endoscopic procedures alone. STUDY
DESIGN: Retrospective review and comparison of outcomes of CA and FESS alone for each CF patient. OUTCOMES MEASURED: sinonasal symptoms, endoscopic findings, number of hospitalizations, antibiotic courses, and forced expiratory volume in 1 second (FEV1).
SETTING: Referral hospital.
RESULTS: Fifteen children underwent CA between 1996 and 2000 (7 males, 8 females; 13.8 years mean age; 42 months average follow-up period). Significant decrease in number of hospitalizations and intravenous antibiotic courses, with increased mean FEV1 (from 70.2% preoperation to 89.3% postoperation, P < 0.0001) were found. Marked clinical improvement persisted for several years.
CONCLUSION: Applying the CA after multiple failed endoscopic procedures in CF patients reduced morbidity and resulted in successful management of sinonasal disease. CA is suggested after multiple failed endoscopic procedures. Further studies of CA as a first-line procedure for difficult sinus cases in children with CF is recommended. EBM RATING: C-4.

Entities:  

Mesh:

Year:  2006        PMID: 16890077     DOI: 10.1016/j.otohns.2006.01.027

Source DB:  PubMed          Journal:  Otolaryngol Head Neck Surg        ISSN: 0194-5998            Impact factor:   3.497


  9 in total

Review 1.  Cystic fibrosis chronic rhinosinusitis: a comprehensive review.

Authors:  Mohamad R Chaaban; Alexandra Kejner; Steven M Rowe; Bradford A Woodworth
Journal:  Am J Rhinol Allergy       Date:  2013 Sep-Oct       Impact factor: 2.467

2.  Extensive surgical and comprehensive postoperative medical management for cystic fibrosis chronic rhinosinusitis.

Authors:  Frank W Virgin; Steven M Rowe; Mary B Wade; Amit Gaggar; Kevin J Leon; K Randall Young; Bradford A Woodworth
Journal:  Am J Rhinol Allergy       Date:  2012 Jan-Feb       Impact factor: 2.467

Review 3.  Rhinosinusitis and comorbidities.

Authors:  Matthew W Ryan; Edward G Brooks
Journal:  Curr Allergy Asthma Rep       Date:  2010-05       Impact factor: 4.806

4.  Outcomes of sinus surgery in adults with cystic fibrosis.

Authors:  Ayesha N Khalid; Jess Mace; Timothy L Smith
Journal:  Otolaryngol Head Neck Surg       Date:  2009-09       Impact factor: 3.497

5.  Medical and Surgical Advancements in the Management of Cystic Fibrosis Chronic Rhinosinusitis.

Authors:  Kiranya E Tipirneni; Bradford A Woodworth
Journal:  Curr Otorhinolaryngol Rep       Date:  2017-02-21

6.  Role of modified endoscopic medial maxillectomy in persistent chronic maxillary sinusitis.

Authors:  Ponnaiah Thulasidas; Venkatraman Vaidyanathan
Journal:  Int Arch Otorhinolaryngol       Date:  2014-02-13

7.  Cystic Fibrosis Foundation otolaryngology care multidisciplinary consensus recommendations.

Authors:  Adam J Kimple; Brent A Senior; Edward T Naureckas; David A Gudis; Ted Meyer; Sarah E Hempstead; Helaine E Resnick; Dana Albon; Wayne Barfield; Margo McKenna Benoit; Daniel M Beswick; Eliza Callard; Shelagh Cofer; Veronica Downer; E Claire Elson; Angela Garinis; Ashleigh Halderman; Lisa Hamburger; Meagan Helmick; Michael McCown; Cameron J McKinzie; Hanna Phan; Kenneth Rodriguez; Ronald C Rubenstein; Ashley Severin; Gopi Shah; Ambika Shenoy; Brittney Sprouse; Frank Virgin; Bradford A Woodworth; Stella E Lee
Journal:  Int Forum Allergy Rhinol       Date:  2022-02-22       Impact factor: 5.426

8.  Sinonasal manifestations in cystic fibrosis.

Authors:  Karin P Q Oomen; Max M April
Journal:  Int J Otolaryngol       Date:  2012-08-05

Review 9.  Chronic rhinosinusitis in cystic fibrosis: a review of therapeutic options.

Authors:  Joanna Krajewska; Krzysztof Zub; Adam Słowikowski; Tomasz Zatoński
Journal:  Eur Arch Otorhinolaryngol       Date:  2021-07-22       Impact factor: 2.503

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.